gatifloxacin has been researched along with Acute Disease in 15 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the clinical efficacy of gatifloxacin with amoxicillin/clavulanate for the treatment of acute otitis media treatment failure and recurrent otitis media." | 9.11 | Randomized, investigator-blinded, multicenter, comparative study of gatifloxacin versus amoxicillin/clavulanate in recurrent otitis media and acute otitis media treatment failure in children. ( Arguedas, A; Biswas, D; Echols, R; Hamed, KA; Husseman, M; Pichichero, M; Pierce, P; Sher, L, 2005) |
| "The bacteriological and clinical efficacy and the safety of gatifloxacin for the treatment of non-complicated acute rhinosinusitis was evaluated in 49 adult patients in an open-label multicenter study in Brazil." | 9.11 | An open multicenter study of the use of gatifloxacin for the treatment of non-complicated acute bacterial rhinosinusitis in adults. ( Campos, CA; Figueiredo, CR; Pignatari, SS; Sakano, E; Weckx, LL, 2005) |
| "We sought to evaluate gatifloxacin in adults with acute uncomplicated bacterial rhinosinusitis." | 9.10 | Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin. ( Nicholson, SC; Pankey, GA; Poole, MD; Sher, LD; Von Seggern, K; Wikler, MA, 2002) |
| "To document the bacteriologic and clinical efficacy of gatifloxacin in recurrent/nonresponsive acute otitis media (AOM)." | 9.10 | Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis study. ( Dagan, R; Echols, RM; Greenberg, D; Hamed, KA; Jacobs, MR; Ledeine, JM; Leiberman, A; Leibovitz, E; Pierce, PF; Piglansky, L; Press, J; Raiz, S, 2003) |
| "This was an open label, multicenter trial in which patients with recurrent otitis media or acute otitis media (AOM) treatment failure were treated with 10 mg/kg gatifloxacin oral suspension once daily for 10 days." | 9.10 | Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure. ( Arguedas, A; Hamed, K; Lopez, E; Pierce, PF; Sáez-Llorens, X; Sher, L; Skuba, K, 2003) |
| "To study the use of prophylactic fourth-generation fluoroquinolone antibiotics, gatifloxacin and moxifloxacin, and bacterial sensitivity in cases of acute postoperative endophthalmitis following cataract surgery." | 7.73 | Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. ( Deramo, VA; Fastenberg, DM; Lai, JC; Udell, IJ, 2006) |
| " Neopterin is a soluble marker of monocyte activation, and elevated levels are of prognostic value in patients with stable coronary artery disease." | 5.12 | Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. ( Braunwald, E; Cannon, CP; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Shui, A, 2007) |
| "To compare the clinical efficacy of gatifloxacin with amoxicillin/clavulanate for the treatment of acute otitis media treatment failure and recurrent otitis media." | 5.11 | Randomized, investigator-blinded, multicenter, comparative study of gatifloxacin versus amoxicillin/clavulanate in recurrent otitis media and acute otitis media treatment failure in children. ( Arguedas, A; Biswas, D; Echols, R; Hamed, KA; Husseman, M; Pichichero, M; Pierce, P; Sher, L, 2005) |
| "The bacteriological and clinical efficacy and the safety of gatifloxacin for the treatment of non-complicated acute rhinosinusitis was evaluated in 49 adult patients in an open-label multicenter study in Brazil." | 5.11 | An open multicenter study of the use of gatifloxacin for the treatment of non-complicated acute bacterial rhinosinusitis in adults. ( Campos, CA; Figueiredo, CR; Pignatari, SS; Sakano, E; Weckx, LL, 2005) |
| "We sought to evaluate gatifloxacin in adults with acute uncomplicated bacterial rhinosinusitis." | 5.10 | Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin. ( Nicholson, SC; Pankey, GA; Poole, MD; Sher, LD; Von Seggern, K; Wikler, MA, 2002) |
| "To document the bacteriologic and clinical efficacy of gatifloxacin in recurrent/nonresponsive acute otitis media (AOM)." | 5.10 | Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis study. ( Dagan, R; Echols, RM; Greenberg, D; Hamed, KA; Jacobs, MR; Ledeine, JM; Leiberman, A; Leibovitz, E; Pierce, PF; Piglansky, L; Press, J; Raiz, S, 2003) |
| "This was an open label, multicenter trial in which patients with recurrent otitis media or acute otitis media (AOM) treatment failure were treated with 10 mg/kg gatifloxacin oral suspension once daily for 10 days." | 5.10 | Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure. ( Arguedas, A; Hamed, K; Lopez, E; Pierce, PF; Sáez-Llorens, X; Sher, L; Skuba, K, 2003) |
| "To study the use of prophylactic fourth-generation fluoroquinolone antibiotics, gatifloxacin and moxifloxacin, and bacterial sensitivity in cases of acute postoperative endophthalmitis following cataract surgery." | 3.73 | Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. ( Deramo, VA; Fastenberg, DM; Lai, JC; Udell, IJ, 2006) |
| "We report the case of a 54-year-old woman who, while being treated for acute sinusitis with gatifloxacin, presented with syncope and was found to have a markedly prolonged QT interval." | 3.72 | Gatifloxacin and prolonged QT interval. ( Ansari, SR; Chopra, N, 2004) |
| " Safety was determined through recording of adverse events." | 2.71 | A randomized, investigator- masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment BID versus QID for the treatment of acute bacterial conjunctivitis of acute bacterial conjunctivitis. ( Bernstein, P; Jensen, H; Schiffman, R; Tepedino, M; Whitcup, SM; Yee, RW, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (93.33) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Griffith, ME | 1 |
| Moon, JE | 1 |
| Johnson, EN | 1 |
| Clark, KP | 1 |
| Hawley, JS | 1 |
| Hospenthal, DR | 1 |
| Murray, CK | 1 |
| Heller, W | 1 |
| Cruz, M | 1 |
| Bhagat, YR | 1 |
| De Leon, JM | 1 |
| Felix, C | 1 |
| Villanueva, L | 1 |
| Hollander, DA | 1 |
| Jensen, H | 2 |
| Sher, LD | 1 |
| Poole, MD | 1 |
| Von Seggern, K | 1 |
| Wikler, MA | 1 |
| Nicholson, SC | 1 |
| Pankey, GA | 1 |
| Leibovitz, E | 1 |
| Piglansky, L | 1 |
| Raiz, S | 1 |
| Greenberg, D | 1 |
| Hamed, KA | 2 |
| Ledeine, JM | 1 |
| Press, J | 1 |
| Leiberman, A | 1 |
| Echols, RM | 1 |
| Pierce, PF | 2 |
| Jacobs, MR | 1 |
| Dagan, R | 1 |
| Arguedas, A | 2 |
| Sher, L | 2 |
| Lopez, E | 1 |
| Sáez-Llorens, X | 1 |
| Hamed, K | 1 |
| Skuba, K | 1 |
| Cheung, O | 1 |
| Chopra, K | 1 |
| Yu, T | 1 |
| Nalesnik, MA | 1 |
| Amin, S | 1 |
| Shakil, AO | 1 |
| Ansari, SR | 1 |
| Chopra, N | 1 |
| Ambrose, PG | 1 |
| Anon, JB | 1 |
| Owen, JS | 1 |
| Van Wart, S | 1 |
| McPhee, ME | 1 |
| Bhavnani, SM | 1 |
| Piedmonte, M | 1 |
| Jones, RN | 1 |
| Yee, RW | 1 |
| Tepedino, M | 1 |
| Bernstein, P | 1 |
| Schiffman, R | 1 |
| Whitcup, SM | 1 |
| Husseman, M | 1 |
| Pichichero, M | 1 |
| Biswas, D | 1 |
| Pierce, P | 1 |
| Echols, R | 1 |
| Weckx, LL | 1 |
| Campos, CA | 1 |
| Sakano, E | 1 |
| Pignatari, SS | 1 |
| Figueiredo, CR | 1 |
| Deramo, VA | 1 |
| Lai, JC | 1 |
| Fastenberg, DM | 1 |
| Udell, IJ | 1 |
| Ray, KK | 1 |
| Morrow, DA | 1 |
| Sabatine, MS | 1 |
| Shui, A | 1 |
| Rifai, N | 1 |
| Cannon, CP | 1 |
| Braunwald, E | 1 |
| Gotfried, MH | 1 |
| DeAbate, CA | 1 |
| Fogarty, C | 1 |
| Mathew, CP | 1 |
| Sokol, WN | 1 |
| Henann, NE | 1 |
| Zambie, MF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00518089] | Phase 3 | 859 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| [NCT00509873] | Phase 3 | 578 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| An Open-Label Noncomparative, Multicenter, Clinical Trail Measuring Time Related Clinical Response Factors in Relation to Time to Bacterial Eradication With Tigecycline Treatment in Patients With Catheter Infection[NCT00419991] | Phase 4 | 10 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| The Effects on Betadine 5% Penetration When Using Lidocaine 2% Jelly Versus Topical Tetracaine 0.5% for Topical Phacoemulsification Cataract Surgery.[NCT00827073] | 40 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye at Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe). (NCT00518089)
Timeframe: Day 6
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 59.6 |
| Placebo Eye Drops | 46.7 |
Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye up to Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe). (NCT00518089)
Timeframe: 6 Days
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 51.8 |
| Placebo Eye Drops | 41.3 |
Percentage of patients with clinical improvement of ocular signs up to Day 6 based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe), defined as a decrease (improvement) from Day 1 (Baseline) in the total score of conjunctival hyperemia and mucopurulent discharge (pus), with no increase (worsening) from Day 1 (Baseline) in either individual variable in the study eye. (NCT00518089)
Timeframe: 6 Days
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 97.0 |
| Placebo Eye Drops | 92.2 |
Percentage of patients with clinical improvement of ocular symptoms, defined as a decrease (improvement) up to Day 6 from Day 1 (Baseline) in the total score of itching and tearing (each on 4-point scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe), with no increase (worsening) from Day 1 (Baseline) in any individual score in the study eye diagnosed with bacterial conjunctivitis. (NCT00518089)
Timeframe: 6 Days
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 92.8 |
| Placebo Eye Drops | 88.6 |
Percentage of patients with microbiological cure, defined such that all bacteria present in the study eye at Day 1 (Baseline) are eradicated up to Day 6 based on a Classification of Microbial Response. (Eradication=pathogen is absent in follow-up culture; Reduction=pathogen is reduced from baseline below threshold count in follow-up culture; Persistence=pathogen reduced from baseline but is above or equal to threshold count in follow-up culture; and Proliferation=pathogen has increased in count from baseline in follow-up culture). (NCT00518089)
Timeframe: 6 Days
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 92.2 |
| Placebo Eye Drops | 80.2 |
Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye at Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe). (NCT00509873)
Timeframe: Day 6
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 74.9 |
| Placebo Eye Drops | 65.2 |
"Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye up to Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe). (Note: The Up to Day 6 analysis included all data up to the Day 6 time point but excluded any Day 6 visit data that was collected after the Day 6 time point)." (NCT00509873)
Timeframe: 6 Days
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 64.1 |
| Placebo Eye Drops | 50.0 |
Percentage of patients with clinical improvement of ocular signs at Day 6 based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe), defined as a decrease (improvement) from Day 1 (Baseline) in the total score of conjunctival hyperemia and mucopurulent discharge (pus),with no increase (worsening) from Day 1 (Baseline) in either individual variable in the study eye. (NCT00509873)
Timeframe: Day 6
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 97.0 |
| Placebo Eye Drops | 96.2 |
Percentage of patients with clinical improvement of ocular symptoms at Day 6, defined as a decrease (improvement) from Day 1 (Baseline) in the total score of itching and tearing (each on 4-point scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe), with no increase (worsening) from Day 1 (Baseline) in any individual score in the study eye diagnosed with bacterial conjunctivitis (NCT00509873)
Timeframe: Day 6
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 85.5 |
| Placebo Eye Drops | 82.2 |
Percentage of patients with microbiological cure, defined such that all bacteria present in the study eye at Day 1 (Baseline) are eradicated (or absent) at Day 6 based on a Classification of Microbial Response. (Eradication=pathogen is absent in follow-up culture; Reduction=pathogen is reduced from baseline below threshold count in follow-up culture; Persistence=pathogen reduced from baseline but is above or equal to threshold count in follow-up culture; and Proliferation=pathogen has increased in count from baseline in follow-up culture) (NCT00509873)
Timeframe: Day 6
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 89.2 |
| Placebo Eye Drops | 61.4 |
Within 3 hours from time of culture acquisition, the samples will be vortexed for 30 seconds and 100µl aliquots will be plated onto 5% sheep blood and chocolate agar plates. These plates will be incubated with 5% carbon dioxide at 35˚ C for 72 hours. After 72 hours all plates will be read for colony count and identification of all isolates will be performed using routine microbiological methods. The natural log of bacterial bacterial colony count will be used for the outcome measure. (NCT00827073)
Timeframe: (1) Pre-antibiotics swab, and (2) Post-study medication (pre surgery)
| Intervention | Ln(bacterial colony count) (Mean) |
|---|---|
| Tetracaine 0.5% Drop | -0.14 |
| Lidocaine 2% Jelly | -0.52 |
(NCT00827073)
Timeframe: (1) Pre-antibiotics swab and (2) Post-study medication (pre surgery)
| Intervention | bacterial spceies (Mean) | |
|---|---|---|
| pre number of bacterial spices | post surgery number of bacterial speices | |
| Lidocaine 2% Jelly | 1 | 1 |
| Tetracaine 0.5% Drop | 1 | 1 |
10 trials available for gatifloxacin and Acute Disease
| Article | Year |
|---|---|
Gatifloxacin 0.5% administered twice daily for the treatment of acute bacterial conjunctivitis in patients one year of age or older.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Pres | 2014 |
Gatifloxacin 0.5% administered twice daily for the treatment of acute bacterial conjunctivitis in patients one year of age or older.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Pres | 2014 |
Gatifloxacin 0.5% administered twice daily for the treatment of acute bacterial conjunctivitis in patients one year of age or older.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Pres | 2014 |
Gatifloxacin 0.5% administered twice daily for the treatment of acute bacterial conjunctivitis in patients one year of age or older.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Pres | 2014 |
Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin.
Topics: Acute Disease; Aged; Anti-Infective Agents; Bacterial Infections; Community-Acquired Infections; Dru | 2002 |
Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis study.
Topics: Acute Disease; Administration, Oral; Child, Preschool; Drug Administration Schedule; Female; Fluoroq | 2003 |
Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure.
Topics: Acute Disease; Administration, Oral; Child; Child, Preschool; Female; Fluoroquinolones; Gatifloxacin | 2003 |
Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis.
Topics: Acute Disease; Anti-Bacterial Agents; Coagulase; Enterobacter aerogenes; Enterobacteriaceae Infectio | 2004 |
A randomized, investigator- masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment BID versus QID for the treatment of acute bacterial conjunctivitis of acute bacterial conjunctivitis.
Topics: Acute Disease; Administration, Oral; Adult; Conjunctivitis, Bacterial; Female; Fluoroquinolones; Gat | 2005 |
Randomized, investigator-blinded, multicenter, comparative study of gatifloxacin versus amoxicillin/clavulanate in recurrent otitis media and acute otitis media treatment failure in children.
Topics: Acute Disease; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Child; Child, P | 2005 |
An open multicenter study of the use of gatifloxacin for the treatment of non-complicated acute bacterial rhinosinusitis in adults.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Bacterial Agents; Female; Fluoroquinolones; Gatifloxaci | 2005 |
Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome.
Topics: Acute Disease; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Biomarkers; Coronary A | 2007 |
Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Double-Blind Metho | 2001 |
5 other studies available for gatifloxacin and Acute Disease
| Article | Year |
|---|---|
Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Ciprofloxacin; Cricetinae; Disease Models, Animal; Do | 2007 |
Gatifloxacin-induced hepatotoxicity and acute pancreatitis.
Topics: Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Female; Fluoroquinolones; Gatifloxacin | 2004 |
Gatifloxacin and prolonged QT interval.
Topics: Acute Disease; Electrocardiography; Female; Fluoroquinolones; Gatifloxacin; Humans; Long QT Syndrome | 2004 |
Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds | 2006 |
Gatifloxacin-associated acute hepatitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Female; Fluoroq | 2001 |